Joseph K Belanoff

CEO Joseph K Belanoff sold 12,837 shares of CORT at $69.74 under scheduled 10b5-1 plan adopted 2024-11-26

Joseph K Belanoff, Chief Executive Officer, sold 12,837 shares (12.8K shares) of CORCEPT THERAPEUTICS INC (CORT) at $69.74 on 2026-06-01 for a total value of $895,252.38 ($895.3K), reducing his holdings from 2,578,326 shares (2.58M shares) to 2,565,489 shares (2.57M shares), a reduction of -0.5% vs pre-transaction holdings. This sale was part of a pre-arranged 10b5-1 trading plan adopted on 2024-11-26, meaning it was scheduled and not discretionary. At the same ticker, Belanoff's prior five trades show mixed performance: recent sells on 2026-05-01 and 2026-03-25 were followed by positive 30-day returns of +38.7% and negative returns of -8.0% respectively, while earlier sales in late 2025 predominantly resulted in negative 90-day returns (-55.2%, -45.2%, and -46.4%). The company reports a net loss of $-31.8M on revenue of $164.9M, with a P/E ratio of 161.82, reflecting a highly valued unprofitable company; the CEO's substantial remaining stake of 2.57M shares demonstrates continued material alignment with shareholder interests despite the liquidation.

CORT CEO sells ~$2M in stock as company navigates recent earnings miss and valuation compression

CEO Joseph Belanoff sold a modest 1.4% of his holdings for roughly $2 million, which alone would be routine. However, the timing reveals an important inflection point: the company delivered a negative earnings surprise last quarter while the stock has nonetheless recovered significantly from its lows and remains well below its peak. Belanoff's sale during a period of near-term weakness in fundamentals—despite the stock's recent 90-day climb—suggests he may be taking profits on the bounce rather than betting on further upside. The company remains profitable and growing revenue year-over-year, but the latest quarter's earnings miss undercuts the growth narrative that likely justified the stock's valuation during its earlier run. This is not a panicked exit; it's a disciplined trim by a leader who may be signaling that current valuations offer a reasonable exit window after weakness.

CEO Belanoff sold 26,198 shares of CORT at $50.07; stock now -67.1% from 52-week high, all 5 prior insider sales here were well-timed

JOSEPH K BELANOFF, Chief Executive Officer, sold 26,198 shares at $50.07 on 2026-03-25 for $1,311,825.55, reducing holdings from 2,944,524 to 2,918,326 shares. The company has strong fundamentals with revenue of $207,638,000.00, net income of $19,668,000.00, and annual revenue growth of +12.8%, yet the stock trades at $37.60, down 67.1% from its 52-week high of $114.22. Notably, this CEO's prior five sales at CORT have displayed a 5-of-5 well-timed pattern at the 90-day mark, with outcomes ranging from -45.2% to -55.2%, and his cross-ticker track record shows a 75.00% well-timed rate across 20 prior sells. The sharp divergence between fundamentals (positive growth, profitable operations, $4.0B market cap) and recent price action (90-day decline of -54.5%) presents a key interpretive tension that warrants monitoring of whether this sale signals recognition of elevated valuation risk or near-term operational headwinds not yet reflected in reported results.

CEO Belanoff sells 40,000 CORT shares at $79.77; stock at $83.67, still -26.8% from 52-week high

CEO Joseph K Belanoff sold 40,000 shares at $79.77 on 2025-12-01, reducing his holdings from 2.74M to 2.70M shares (-1.5%). The stock currently trades at $83.67, down -26.8% from its 52-week high of $114.22, despite a strong +12.8% 30-day and +20.6% 90-day price action. Belanoff's cross-ticker track record shows 20 prior sells with a 61.54% well-timed rate (sales preceding declines), though at CORT specifically, his 5 prior trades remain largely unmeasured—only one shows a measurable 30-day outcome (+13.0% on 2025-11-03 sell, meaning the stock rose after that sale). The CEO's recent activity at this stock includes three additional sells just days earlier on 2025-11-05, suggesting sustained selling pressure. Fundamentals remain solid: $207.6M quarterly revenue, $19.7M net income, and +39.9% annual revenue growth; however, the P/E of 82.84 reflects substantial valuation premium. The confluence of CEO selling into a steep drawdown from highs, combined with repeated recent dispositions and elevated valuation multiples, merits observation.

CEO Joseph Belanoff sold 40,000 shares of CORT for $2,983,119.09 across 4 transactions (Nov 3–5).

CEO Joseph K. Belanoff executed 4 separate sales totaling 40,000 shares for $2,983,119.09 between November 3–5, 2025, at a blended average price of $74.58, reducing his holdings by 1.4% to 2,741,370 shares. The timing is notable: the stock has since declined 14.7% over the 30-day period and is now trading at $76.65, 32.9% below its 52-week high of $114.22. Belanoff's prior sales at this ticker (5 trades in the same-ticker history) have shown mixed results—three October sales each posted negative 30-day returns of 12.8% to 14.2%, while two September sales posted positive returns of 20.4% and 21.2%—demonstrating no discernible same-ticker pattern. His cross-ticker track record shows a 90-day well-timed rate of 80.00%, but the measurable outcomes at CORT itself remain too recent (90-day results not yet determinable for the October and November 2025 sales). Given the company's strong fundamental position—revenue of $207,638,000.00, net income of $19,668,000.00, annual revenue growth of 39.9%, and a P/E of 75.89—the sale appears to be a routine open-market adjustment rather than a signal of fundamental concern.

CEO Joseph Belanoff sells 40,000 CORT shares across 3 transactions for $3.4M at blended $85.08, retaining 2.78M shares

Joseph Belanoff, Chief Executive Officer of Corcept Therapeutics, executed 3 separate sales on 2025-10-01 totaling 40,000 shares for $3,403,252.83 at prices ranging from $84.29 to $85.67. The sale reduced his holdings by 1.4% from 2,821,370 to 2,781,370 shares. Notably, his prior trades at CORT show mixed near-term outcomes: recent September sales posted 30-day returns of +21.2% and +20.4%, while August sales showed minimal positive returns of +0.1% to +2.8%. His cross-ticker track record spans 17 prior sells with a 100.00% well-timed rate at the 90-day mark, though outcomes at this ticker are not yet measurable beyond 30 days. The company trades at a P/E of 69.41 with 39.9% annual revenue growth, and the stock has appreciated 23.6% over 30 days and 22.0% over 90 days from the transaction date.

CORT CEO Joseph Belanoff sold 40,000 shares for $2.8M at $70.53 blended average on 2025-09-02.

Joseph Belanoff, CORT's CEO, executed 2 separate sales totaling 40,000 shares for $2,821,033.45, reducing his holdings from 2.86M to 2.82M shares (-1.4%). The blended average sale price of $70.53 sits 1.7% above the current price of $69.37 and 38.3% below the 52-week high of $114.22. His cross-ticker track record across all open-market sales shows a 100% well-timed rate at the 90-day mark (average 90-day return: -16.0%), though at CORT specifically, his 2 prior measurable sales (June 2025) also proved well-timed with -13.2% and -14.3% respective returns. The company reports strong fundamentals: $194.4M quarterly revenue, $35.1M net income, and 39.9% annual revenue growth, though the stock trades at a notably elevated 54.62 P/E ratio. This sale occurs as the stock has declined 1.5% over 30 days and 0.3% over 90 days from prior sales, and current valuation remains significantly compressed from recent peaks.

CORT CEO Belanoff sells 40,000 shares for $2.7M across 3 transactions on 2025-08-01

Joseph K. Belanoff, CEO of Corcept Therapeutics, executed 3 separate sales totaling 40,000 shares for $2,741,207.37 (blended average $68.53) on 2025-08-01, reducing his holdings from 2.90M to 2.86M shares (-1.4%). The stock has declined 2.5% over the past 30 days and currently trades at $70.45, down 38.3% from its 52-week high of $114.22. Across his 5 prior open-market sales at CORT (all on 2025-06-02), Belanoff's 30-day outcomes ranged from -12.3% to -16.1%, establishing a pattern of selling into subsequent weakness at this ticker. His cross-ticker track record shows 12 prior sells with a 100.0% well-timed rate (90-day average return -18.6%), indicating consistent execution of sales ahead of declines. The filing occurs in a context of the stock trading significantly below peak valuation, with fundamentals showing strong growth: annual revenue growth of +39.9%, net income of $35,149,000.00, and a P/E of 55.47.

CORT CEO Joseph Belanoff sold 40,000 shares for $3.3M on 2025-06-02; stock down 38.7% from 52-week high at $114.22.

Joseph K Belanoff, Chief Executive Officer of Corcept Therapeutics, executed 8 separate sales totaling 40,000 shares for $3,314,309.74 on 2025-06-02, with transaction prices ranging from $78.42 to $84.57 (blended average $82.86). The sale reduces his post-transaction holdings to 2,901,985 shares, a net reduction of 1.4% from his pre-transaction position. The current stock price of $69.98 sits 38.7% below the 52-week high of $114.22, and his prior four sales at this ticker show mixed timing outcomes: two returned +5.9% and +7.0% over 30 days (in early May), while two earlier sales returned -37.7% and -24.1% over 30 days. His cross-ticker track record of 4 prior sells averaged -12.2% return over 30 days. With the company reporting revenue of $157,214,000.00, net income of $20,547,000.00, annual growth of +39.9%, and a P/E of 55.54, investors should monitor whether this large insider sale by the CEO signals reassessment of near-term valuation or represents opportunistic portfolio management amid stock volatility.

CORT CEO Joseph Belanoff sells 40,000 shares (1.3% of holdings) for $2.9M; largest sale in recent pattern

Joseph K Belanoff, Chief Executive Officer of Corcept Therapeutics, executed 2 separate sales totaling 40,000 shares for $2,915,921.76 on 2025-05-02 at a blended average price of $72.90. This $2.9M transaction reduces his holdings to 2,941,985 shares post-transaction. The stock currently trades at $73.94, near the transaction price, but is -35.3% from its 52-week high of $114.22. Notably, Belanoff has established a pattern of recent sales: he sold on both 2025-04-01 and 2025-03-31, and in both prior same-ticker instances, the stock declined in the 30 days following each sale (down -37.7% and -24.1% respectively). His cross-ticker track record shows 2 prior open-market sells with an average 30-day return of -30.9%, though 90-day outcomes remain limited and do not yet show a measurable pattern of well-timed exits. The timing pattern line indicates 0 of 0 prior sells were well-timed at the 90-day mark—reflecting that those outcomes are not yet measurable. This concentrated sequence of three sales within five trading days, coupled with recent negative post-sale price action, warrants investor attention to whether the CEO perceives near-term headwinds despite the company's strong fundamentals (revenue $157.2M in the latest quarter, net income $20.5M, annual revenue growth of +39.9%).